Grants Search Results

This institution is a member of a research project which is being funded by St. Baldrick's: The AML Federation Project. For a description of this project, see the consortium grant made to the lead institution: Sage Bionetworks, Seattle, WA.

This institution is a member of a research project which is being funded by St. Baldrick's: The AML Federation Project. For a description of this project, see the consortium grant made to the lead institution: Sage Bionetworks, Seattle, WA.

This institution is a member of a research project which is being funded by St. Baldrick's: The AML Federation Project. For a description of this project, see the consortium grant made to the lead institution: Sage Bionetworks, Seattle, WA.

Most children treated for cancer can now expect to be cured. However, in a significant majority, future fertility may be compromised by their disease or its treatment. Girls are particularly at risk to ovarian injury. These children are cured; however the girls will live the rest of their life in menopause and they will also sadly be unable to have a child of their own. Dr. Lukish's work aims to open the field of ovarian cryopreservation in children by providing an evidence base for future practice, with significant potential benefit to young girls with cancer.

Leukemia cells divide extensively, often by hijacking mechanisms that regulate normal stem cells. Dr. Magee is working to characterize genes that potentially regulate the growth of normal stem cells and leukemia cells. By characterizing these genes, Dr. Magee's team hopes that the proteins encoded by these genes will become targets for novel anti-leukemia therapies.

Based on progress to date, Dr. Mar was awarded a new grant in 2017 to fund an additional year of this Scholar award. Although many children with acute lymphoblastic leukemia (ALL) are being cured today, a significant number still relapse. New targeted therapies that specifically attack the biology of ALL have great potential to improve outcomes; however, few specific biological vulnerabilities have been identified so far. Dr. Mar's team recently used a method to find novel biological vulnerabilities specific to ALL. As the Ben's Green Drakkoman Fund St. Baldrick's Scholar, Dr. Mar is studying those novel vulnerabilities in leukemia models, with the goal to understand why they are essential to ALL, and to determine their suitability for therapy.

This grant is named for the Ben's Green Drakkoman Fund, created to honor the memory of Ben Stowell who battled osteosarcoma with an inspiring determination to live life fully. The fund is named after a super hero Ben created named the Green Drakkoman who defeats his enemy, the Evil Alien.

Langerhans cell histiocytosis (LCH) is a very rare type of neoplasm of the blood that has not been well investigated. It has been traditionally excluded from the major cooperative research groups, and thus considered an orphan disease. However, LCH affects many children. This consortium uses a uniform treatment while investigating the biology of the disease to seek for better therapeutic targets. Awarded at Dana-Farber Cancer Institute and transferred to St. Jude Children's Research Hospital. Funds administered by St. Jude Children's Research Hospital.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

Based on progress to date, Dr. Shand was awarded new grants in 2017 and 2018 to fund additional years of this Scholar award. Leukemia is a blood cancer that kills more children than any other cancer. Dr. Shand's work is based on the belief that leukemia behaves like some infections do, by tricking our body into thinking it's OK to set up shop there. Dr. Shand is studying how leukemia can send these "trick signals" to the part of our body that fights off infections, the immune system. This research aims to understand how these trick signals work, with the goal of turning them off so that the immune system can be used to cure leukemia.

This grant is generously supported by Micaela's Army Foundation, a St. Baldrick's partner which was founded in loving memory of Micaela White who fiercely fought Acute Myeloid Leukemia at the age of 18. Their mission is to raise money to help fund cancer research, education, awareness, and patient support for the cancers that affect children and their families.

While many children with leukemia experience good outcomes on modern therapies, there are a large number of children who still relapse and die of their disease. Using new methods, Dr. Willman identified a new form of leukemia, called Ph-like ALL, which has a variety of gene mutations which code for enzymes. Currently, drugs that inhibit these enzymes are available for clinical trials. Dr. Willman is testing these drugs in children with high risk leukemia. This research aims to extend Dr. Willman's current studies to include children with standard risk leukemia in order to also improve their chances of survival.

Based on progress to date, Dr. Zhang was awarded new grants in 2017 and 2018 to fund additional years of this International Scholar award. Though cure rates have improved dramatically, geographic inequities in childhood acute lymphoblastic leukemia (ALL) therapy remain evident between developed vs. low-middle income countries. In China, about 7,700 newly-diagnosed children with ALL every year receive therapy thanks to the coverage provided by a special national health insurance scheme established in 2010. With the drastic increase in access to clinical care, the challenge is now shifting from remedying the inability to pay for ALL therapy to delivering better therapy and improving outcome. Dr. Zhang is working to bring improved therapy to China. This represents an unprecedented opportunity for translational research of childhood ALL in China, with potential impacts for a large number of patients.